June 2-6, 2023
This year's meeting will be in-person in Chicago and online.
The American Society of Clinical Oncology (ASCO) annual meeting offers premier scientific events for oncology professionals, patient advocates, industry representatives and major media outlets worldwide.
The 2023 ASCO annual meeting, held in Chicago, provides an opportunity to learn about the latest developments in cancer science from Fred Hutchinson Cancer Center and research institutions around the world. The program features more than 200 sessions complementing the meeting’s theme: Partnering with Patients - The Cornerstone of Cancer Care and Research.
Fred Hutchinson Cancer Research Center and Seattle Cancer Care Alliance have merged to form Fred Hutchinson Cancer Center, a unified adult cancer research and care center that brings together SCCA and Fred Hutchinson Cancer Research Center into a single, independent, nonprofit organization that is also a clinically integrated part of UW Medicine and UW Medicine’s cancer program.
Oral Abstract | Poster Discussion Session | Poster Session | Publication Only
Oral Abstract: Enhancing prediction of cancer therapy-related cardiomyopathy from surveillance echocardiograms: A Children’s Oncology Group (COG) report.
Presenter: Eric Chow
Monday, June 5, 9:00 a.m. - 9:12 a.m. (CT)
Oral Abstract: Non-comparative, open-label, international, multicenter phase I/II study of nivolumab (NIVO) ± ipilimumab (IPI) in patients (pts) with recurrent/metastatic Merkel cell carcinoma (MCC) (CheckMate 358).
Presenter: Shailender Bhatia
Monday, June 5, 5:00 p.m. - 5:12 p.m. (CT)
Oral Abstract: A phase I trial of dose-adjusted EPOCH plus inotuzumab ozogamicin (InO) in adults with relapsed/refractory (R/R) B lymphoblastic leukemia/lymphoma (B-ALL).
Presenter: Noam Kopmar
Friday, June 2, 3:12 p.m. - 3:24 p.m. (CT)
Oral Abstract: Evaluation of change in RECIST tumor size and survival in patients with rare cancers treated with checkpoint inhibitor therapy (SWOG S1609).
Presenter: Megan Othus
Sunday, June 4, 10:49 a.m. - 11:01 a.m. (CT)
Oral Abstract: Risk of early mortality in patients with cancer experiencing adverse financial events.
Presenter: Hiba Khan
Tuesday, June 6, 9:00 a.m. - 9:12 a.m. (CT)
Poster Discussion Session: A phase I study of nanoparticle albumin-bound sirolimus (NAB-S) combined with pazopanib (PAZO) in patients with advanced soft tissue sarcoma (STS).
Presenter: Lee Cranmer
Saturday, June 3, 4:30 p.m. - 6:00 p.m. (CT)
Poster Discussion Session: Fibroblast growth factor receptor 3 (FGFR3) alterations in PROOF 302: A phase III trial of infigratinib (BGJ398) as adjuvant therapy in patients (pts) with invasive urothelial carcinoma (UC).
Presenter: Petros Grivas
Saturday, June 3, 3:00 p.m. - 4:30 p.m. (CT)
Poster Discussion Session: Dual PD1 and CTLA4 immune checkpoint blockade and hypofractionated radiation in patients with salivary gland cancers.
Presenter: Cristina Rodriguez
Monday, June 5, 4:30 p.m. - 6:00 p.m. (CT)
Poster Discussion Session: Five-year follow-up update of defined-composition CD19 CAR T-cell therapy for relapsed/refractory CLL.
Presenter: Emily Liang
Monday, June 5, 1:15 p.m. - 2:45 p.m. (CT)
Poster Discussion Session: The impact of adverse financial events on healthcare utilization and treatment costs at the end of life.
Presenter: Chipo Kwendakwema
Saturday, June 3, 4:30 p.m. - 6:00 p.m. (CT)
Poster Session: Preclinical testing of FOLR1-CAR T cells against osteosarcoma (OS).
Presenter: Michelle Choe
Saturday, June 3, 8:00 a.m. - 11:00 a.m. (CT)
Poster Session: Long-term efficacy and safety of pembrolizumab with R-CHOP as first-line therapy for DLBCL.
Presenter: Carrie Ho
Monday, June 5, 8:00 a.m. - 11:00 a.m. (CT)
Poster Session: Evaluation of cardiac failure and recovery in acute myelogenous leukemia.
Presenter: Matthew Wu
Monday, June 5, 8:00 a.m. - 11:00 a.m. (CT)
Poster Session: The somatic mutation profile of breast cancer in Uganda.
Presenter: Manoj Menon
Sunday, June 4, 8:00 a.m. - 11:00 a.m. (CT)
Poster Session: PSMA expression and response to 177Lu-PSMA-617 (LuPSMA) in men with vs. without DNA damage repair (DDR) mutations.
Presenter: Ruben Raychaudhuri
Saturday, June 3, 8:00 a.m. - 11:00 a.m. (CT)
Poster Session: Final results of a pilot study of docetaxel and carboplatin for treatment of patients with mCRPC containing biallelic inactivation of genes in the homologous recombination DNA repair pathway.
Presenter: Ruben Raychaudhuri
Saturday, June 3, 8:00 a.m. - 11:00 a.m. (CT)
Poster Session: Outcomes among adult recipients of CD19 CAR T-cell therapy for Burkitt lymphoma.
Presenter: Laura Samples
Monday, June 5, 8:00 a.m. - 11:00 a.m. (CT)
Poster Session: Impact of COVID-19 pandemic mitigation strategies on industry and NCI cancer treatment trials.
Presenter: Joseph Unger
Monday, June 5, 1:15 p.m. - 4:15 p.m. (CT)
Poster Session: Impact of the COVID-19 pandemic on insurance transitions among commercially insured cancer patients in Washington state.
Presenter: Scott Ramsey
Saturday, June 3, 1:15 p.m. - 4:15 p.m. (CT)
Poster Session: Molecular testing utilization in patients with advanced non-small cell lung cancer (NSCLC) in Washington (WA) state.
Presenter: Veena Shankaran
Saturday, June 3, 1:15 p.m. - 4:15 p.m. (CT)
Poster Session: Preclinical evaluation of targeting PRAME with TCR mimic CAR T cells in AML.
Presenter: Danielle Kirkey
Saturday, June 3, 8:00 a.m. - 11:00 a.m. (CT)
Poster Session: Use of germline testing in patients with prostate, pancreatic, or ovarian cancer in Washington (WA) state.
Presenter: Veena Shankaran, Qin Sun
Saturday, June 3, 1:15 p.m. - 4:15 p.m. (CT)
Poster Session: Differential responses to systemic therapy among patients who are financially fragile and receiving Medicaid: Results from ePRO and biometric monitoring study.
Presenter: Scott Ramsey
Monday, June 5, 1:15 p.m. - 4:15 p.m. (CT)
Poster Session: Phase I/II randomized clinical trial of in-clinic acupuncture prior to BCG in patients with high-risk non-muscle invasive bladder cancer.
Presenter: Sarah Psutka
Saturday, June 3, 8:00 a.m. - 11:00 a.m. (CT)
Poster Session: Identification of factors to predict low risk febrile neutropenia admissions in patients with acute myeloid leukemia (AML) following intensive chemotherapy.
Presenter: Khushboo Pal
Monday, June 5, 8:00 a.m. - 11:00 a.m. (CT)
Poster Session: Implications for acute myeloid leukemia (AML) treatment and care during the COVID-19 pandemic: A Connect Myeloid Registry study.
Presenter: Bart Scott
Monday, June 5, 8:00 a.m. - 11:00 a.m. (CT)
Poster Session: Safety and clinical activity of oleclumab (O) ± durvalumab (D) + chemotherapy (CT) in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC): A phase 1b/2 randomized study.
Presenter: Andrew Coveler
Monday, June 5, 8:00 a.m. - 11:00 a.m. (CT)
Poster Session: Phase 1 results of CYT-0851, a monocarboxylate transporter (MCT) inhibitor, in combination with capecitabine (cape) or gemcitabine (gem) in advanced solid tumors.
Presenter: Ryan Lynch
Saturday, June 3, 8:00 a.m. - 11:00 a.m. (CT)
Poster Session: Outcomes with immune checkpoint inhibitors (ICI) in patients (pts) with MTAP alterations (alt) in advanced urothelial carcinoma (aUC).
Presenter: Rafee Talukder
Saturday, June 3, 8:00 a.m. - 11:00 a.m. (CT)
Publication Only: Effect of change in ECOG performance status at diagnosis and relapse in patients with acute myeloid leukemia.
Presenter: Michelle Zhang
Publication Only: Attachment avoidance and anxiety impacting dyadic coping and communication in patients with metastatic sarcoma and their family caregivers.
Presenter: Courtney Daum
Publication Only: Comparison of conventional clinical models and a multigene assay to assess DCIS risk in a prospective single center study.
Presenter: Loise Wairiri
Publication Only: Osimertinib rechallenge in advanced EGFR non-small cell lung cancer patients.
Presenter: Natalie Uy
Changes in RECIST Tumor Measures Correlate Linearly With Survival in Patients Treated With Checkpoint Inhibitors
The ASCO Post | June 4, 2023